NO20002960L - Anvendelse av en aromataseinhibitor ved behandling av redusert androgen:østrogen-forhold og detrusor uretral sfinkter- dyssyneri hos menn, samt metode for undersøkelse av dyssynergi hos hanngnagere - Google Patents
Anvendelse av en aromataseinhibitor ved behandling av redusert androgen:østrogen-forhold og detrusor uretral sfinkter- dyssyneri hos menn, samt metode for undersøkelse av dyssynergi hos hanngnagereInfo
- Publication number
- NO20002960L NO20002960L NO20002960A NO20002960A NO20002960L NO 20002960 L NO20002960 L NO 20002960L NO 20002960 A NO20002960 A NO 20002960A NO 20002960 A NO20002960 A NO 20002960A NO 20002960 L NO20002960 L NO 20002960L
- Authority
- NO
- Norway
- Prior art keywords
- men
- urethral sphincter
- bladder
- dyssynergy
- treatment
- Prior art date
Links
- 241000283984 Rodentia Species 0.000 title abstract 3
- 239000003098 androgen Substances 0.000 title abstract 3
- 239000000262 estrogen Substances 0.000 title abstract 3
- 229940011871 estrogen Drugs 0.000 title abstract 3
- 210000005070 sphincter Anatomy 0.000 title abstract 3
- 229940122815 Aromatase inhibitor Drugs 0.000 title abstract 2
- 239000003886 aromatase inhibitor Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 230000002485 urinary effect Effects 0.000 abstract 3
- 210000003205 muscle Anatomy 0.000 abstract 2
- 206010003591 Ataxia Diseases 0.000 abstract 1
- 238000010171 animal model Methods 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000027939 micturition Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000523 sample Substances 0.000 abstract 1
- 210000003708 urethra Anatomy 0.000 abstract 1
- 210000001635 urinary tract Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Accommodation For Nursing Or Treatment Tables (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/989,447 US5972921A (en) | 1997-12-12 | 1997-12-12 | Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men |
| PCT/FI1998/000954 WO1999030708A2 (en) | 1997-12-12 | 1998-12-09 | Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men and method to study the dyssynergia in male rodents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20002960D0 NO20002960D0 (no) | 2000-06-09 |
| NO20002960L true NO20002960L (no) | 2000-08-14 |
Family
ID=25535123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20002960A NO20002960L (no) | 1997-12-12 | 2000-06-09 | Anvendelse av en aromataseinhibitor ved behandling av redusert androgen:østrogen-forhold og detrusor uretral sfinkter- dyssyneri hos menn, samt metode for undersøkelse av dyssynergi hos hanngnagere |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US5972921A (ja) |
| EP (1) | EP1043993B1 (ja) |
| JP (1) | JP2002508322A (ja) |
| KR (1) | KR20010032909A (ja) |
| CN (1) | CN1281361A (ja) |
| AT (1) | ATE235904T1 (ja) |
| AU (1) | AU743196B2 (ja) |
| BR (1) | BR9813534A (ja) |
| CA (1) | CA2312347A1 (ja) |
| DE (1) | DE69813025T2 (ja) |
| EE (1) | EE200000346A (ja) |
| ES (1) | ES2191358T3 (ja) |
| HU (1) | HUP0100762A3 (ja) |
| NO (1) | NO20002960L (ja) |
| NZ (1) | NZ504632A (ja) |
| PL (1) | PL341653A1 (ja) |
| WO (1) | WO1999030708A2 (ja) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5972921A (en) | 1997-12-12 | 1999-10-26 | Hormos Medical Oy Ltd. | Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men |
| BR0013272B1 (pt) | 1999-08-13 | 2013-10-15 | Uso de um inibidor de aromatase esteroidal | |
| US20030083342A1 (en) * | 2002-08-27 | 2003-05-01 | Steele Ronald Edward | Combination of organic compounds |
| SK14612002A3 (sk) * | 2000-04-12 | 2003-05-02 | Novartis Ag | Farmaceutická kompozícia obsahujúca inhibítor aldosterónsyntázy prípadne v kombinácii s antagonistom AT1-receptora a jej použitie |
| US6495534B2 (en) * | 2000-05-15 | 2002-12-17 | Pharmacia & Upjohn Spa | Stabilized aqueous suspensions for parenteral use |
| FI20010905A0 (fi) * | 2001-05-02 | 2001-05-02 | Vetcare Oy | Uusi eläinlääke |
| US6607755B2 (en) | 2001-06-21 | 2003-08-19 | Michael Donald Farley | Anti-aromatase pharmaceutical composition for controlling testosterone/estrone ratios |
| US6931276B2 (en) * | 2002-04-29 | 2005-08-16 | Tomi Streng | Method and device for use in micturition studies |
| US20040248989A1 (en) | 2003-06-05 | 2004-12-09 | Risto Santti | Method for the treatment or prevention of lower urinary tract symptoms |
| EP1656129A4 (en) * | 2003-08-22 | 2009-03-11 | Univ Virginia | MTOR BLOCUS FOR PREVENTING HORMONE ADAPTIVE RESPONSE |
| CN101448490A (zh) * | 2006-05-22 | 2009-06-03 | 霍尔莫斯医疗有限公司 | 治疗慢性非细菌性前列腺炎的选择性雌激素受体调节剂或者芳香酶抑制剂 |
| BR112014005434B1 (pt) * | 2011-09-08 | 2021-01-05 | Novartis Ag | Composições farmacêuticas compreendendo inibidor da aromatase 4,4'-[fluoro-(1h-1,2,4triazol-1-il)metilemo]bisbenzonitrila e seu método de preparação |
| CN102641502A (zh) * | 2012-04-25 | 2012-08-22 | 中国农业大学 | 芳香酶抑制剂的新用途 |
| JP6545185B2 (ja) * | 2014-03-21 | 2019-07-17 | ドン・ワ・ファーム・カンパニー・リミテッドＤｏｎｇ Ｗｈａ Ｐｈａｒｍ． Ｃｏ．， Ｌｔｄ． | インドナガコショウ抽出物を含む排尿障害の予防、治療及び改善用組成物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2273704B (en) * | 1992-12-16 | 1997-01-22 | Orion Yhtymae Oy | Triazolyl diaryl selective aromatase inhibiting compounds |
| DE4435368A1 (de) | 1994-09-22 | 1996-03-28 | Schering Ag | Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann |
| US5972921A (en) | 1997-12-12 | 1999-10-26 | Hormos Medical Oy Ltd. | Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men |
-
1997
- 1997-12-12 US US08/989,447 patent/US5972921A/en not_active Expired - Fee Related
-
1998
- 1998-09-12 US US09/581,128 patent/US6316431B1/en not_active Expired - Lifetime
- 1998-12-09 CN CN98812074A patent/CN1281361A/zh active Pending
- 1998-12-09 WO PCT/FI1998/000954 patent/WO1999030708A2/en not_active Application Discontinuation
- 1998-12-09 BR BR9813534-1A patent/BR9813534A/pt not_active IP Right Cessation
- 1998-12-09 PL PL98341653A patent/PL341653A1/xx unknown
- 1998-12-09 ES ES98958935T patent/ES2191358T3/es not_active Expired - Lifetime
- 1998-12-09 HU HU0100762A patent/HUP0100762A3/hu unknown
- 1998-12-09 NZ NZ504632A patent/NZ504632A/en unknown
- 1998-12-09 AU AU14897/99A patent/AU743196B2/en not_active Ceased
- 1998-12-09 EP EP98958935A patent/EP1043993B1/en not_active Expired - Lifetime
- 1998-12-09 EE EEP200000346A patent/EE200000346A/xx unknown
- 1998-12-09 KR KR1020007006244A patent/KR20010032909A/ko not_active Application Discontinuation
- 1998-12-09 AT AT98958935T patent/ATE235904T1/de not_active IP Right Cessation
- 1998-12-09 JP JP2000538691A patent/JP2002508322A/ja active Pending
- 1998-12-09 CA CA002312347A patent/CA2312347A1/en not_active Abandoned
- 1998-12-09 DE DE69813025T patent/DE69813025T2/de not_active Expired - Lifetime
-
2000
- 2000-06-09 NO NO20002960A patent/NO20002960L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2312347A1 (en) | 1999-06-24 |
| EP1043993B1 (en) | 2003-04-02 |
| JP2002508322A (ja) | 2002-03-19 |
| NO20002960D0 (no) | 2000-06-09 |
| BR9813534A (pt) | 2000-11-14 |
| HUP0100762A3 (en) | 2002-12-28 |
| US5972921A (en) | 1999-10-26 |
| DE69813025T2 (de) | 2004-01-15 |
| AU743196B2 (en) | 2002-01-24 |
| DE69813025D1 (de) | 2003-05-08 |
| ES2191358T3 (es) | 2003-09-01 |
| US6316431B1 (en) | 2001-11-13 |
| KR20010032909A (ko) | 2001-04-25 |
| EP1043993A2 (en) | 2000-10-18 |
| WO1999030708A3 (en) | 1999-08-19 |
| ATE235904T1 (de) | 2003-04-15 |
| WO1999030708A2 (en) | 1999-06-24 |
| HUP0100762A2 (hu) | 2001-08-28 |
| CN1281361A (zh) | 2001-01-24 |
| PL341653A1 (en) | 2001-04-23 |
| EE200000346A (et) | 2001-10-15 |
| AU1489799A (en) | 1999-07-05 |
| NZ504632A (en) | 2001-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20002960L (no) | Anvendelse av en aromataseinhibitor ved behandling av redusert androgen:østrogen-forhold og detrusor uretral sfinkter- dyssyneri hos menn, samt metode for undersøkelse av dyssynergi hos hanngnagere | |
| Christ et al. | Increased connexin43-mediated intercellular communication in a rat model of bladder overactivity in vivo | |
| Hijaz et al. | Animal models of female stress urinary incontinence | |
| Farouk et al. | Abnormal transient internal sphincter relaxation in idiopathic pruritus ani: physiological evidence from ambulatory monitoring | |
| Kamo et al. | The role of bladder-to-urethral reflexes in urinary continence mechanisms in rats | |
| Bradley | Urinary bladder dysfunction in multiple sclerosis | |
| Patel et al. | Pancreatic interstitial pH in human and feline chronic pancreatitis | |
| WO2007079271A2 (en) | Techniques for evaluating urinary stress incontinence | |
| Lee et al. | Simultaneous registration of intraabdominal and intravesical pressures during cystometry in conscious rats—effects of bladder outlet obstruction and intravesical PGE2 | |
| Kamo et al. | Functional analysis of active urethral closure mechanisms under sneeze induced stress condition in a rat model of birth trauma | |
| Eri et al. | A prospective, placebo-controlled study of the antiandrogen Casodex as treatment for patients with benign prostatic hyperplasia | |
| Corona‐Quintanilla et al. | The role of pelvic and perineal striated muscles in urethral function during micturition in female rabbits | |
| Melman et al. | Evaluation of two techniques of partial urethral obstruction in the male rat model of bladder outlet obstruction | |
| CN101485592B (zh) | 电液化前列腺组织治疗探头 | |
| Shafik | Straining urethral reflex: description of a reflex and its clinical significance: preliminary report | |
| Nordling et al. | Urethral electromyography using a new ring electrode | |
| Petros et al. | A mathematical model for micturition gives new insights into pressure measurement and function | |
| Melman et al. | Longitudinal studies of time‐dependent changes in both bladder and erectile function after streptozotocin‐induced diabetes in Fischer 344 male rats | |
| Kirby et al. | Non‐obstructive detrusor failure. A urodynamic, electromyographic, neurohistochemical and autonomic study | |
| Ko et al. | Treatment of external urethral sphincter hypertonicity by pudendal nerve block using phenol solution in patients with spinal cord injury | |
| Ito et al. | Characterization of mouse neuro‐urological dynamics in a novel decerebrate arterially perfused mouse (DAPM) preparation | |
| Kim et al. | Diabetes slows the recovery from urinary incontinence due to simulated childbirth in female rats | |
| Reber et al. | Feline model of chronic obstructive pancreatitis: effects of acute pancreatic duct decompression on blood flow and interstitial pH | |
| Bradley et al. | Neuromuscular dysfunction of the lower urinary tract in patients with lesions of the cauda equina and conus medullaris | |
| Hasegawa et al. | The effect of abdominal pressure on urinary flow rate |